doxifluridine has been researched along with Signet Ring Cell Carcinoma in 2 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 1 (50.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Fukasawa, T; Gotoh, H; Shoji, T; Taniwaka, K | 1 |
Hoshino, K; Ikeda, H; Kamoshita, N; Kobayashi, J; Koyama, T; Morishita, Y; Nakamura, M; Tanaka, T | 1 |
2 other study(ies) available for doxifluridine and Signet Ring Cell Carcinoma
Article | Year |
---|---|
[A long-term survivor with stage IV gastric cancer due to postoperative weekly paclitaxel and 5'-DFUR combination therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Combined Modality Therapy; Drug Administration Schedule; Female; Floxuridine; Gastrectomy; Humans; Lymph Node Excision; Lymph Nodes; Lymphatic Metastasis; Middle Aged; Neoplasm Staging; Paclitaxel; Quality of Life; Salvage Therapy; Stomach Neoplasms; Survivors | 2006 |
[Unresectable gastric cancer followed by remarkably effective tumor disappearance and good quality of life for 10 months after CDDP/5'-DFUR combination chemotherapy--a case report].
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Carcinoma, Signet Ring Cell; Cisplatin; Esophageal Neoplasms; Female; Floxuridine; Humans; Infusions, Intravenous; Liver Neoplasms; Lymphatic Metastasis; Neoplasm Invasiveness; Quality of Life; Stomach Neoplasms | 1996 |